Importantly, QuoNova’s QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of infection from such drug-resistant bacteria, without inducing resistance itself. QuoNova recently demonstrated the efficacy of its QSB technology in a predictive animal model where QSBs significantly reduced the ability of clinically relevant bacteria to colonize secondary burn wounds. In addition, a marked synergy with Silver Sulfadiazine (SSD), a commonly used antibacterial preparation, was observed.
Heiri Gugger, CEO of QuoNova, said: “These are promising results which significantly broaden the reach of our platform and further illustrate the impact of QuoNova’s QSB technology in combating the detrimental effects of biofilms.”